Latest Headlines

Latest Headlines

Still reeling from China bribery probe, GSK faces corruption scandal in Syria

The British company said Thursday that it had received an email containing allegations from a whistleblower pertaining to bribes paid by GSK's consumer healthcare operation in Syria before it was shut down amidst the country's civil war in 2012.

Startups like Kinetic Medical take the lead in the Chinese device market

China's Kinetic Medical is taking its cues from foreign companies like Medtronic but has local advantages as well. While co-founder Jay Qin says its products are of comparable quality as international brands, he believes Kinetic's popularity stems from better understanding of domestic practices, insuring his company was able to grab up loyal customers from its inception as a small, three-man startup in 2005.

German Merck to start work on new China plant

Merck KGaA will start construction next month on a plant to make diabetes drugs in China, a market it says is key to its future. The market is so important that the executive board of the German drugmaker held an event there to reiterate that point to Chinese officials.

China allows trial of investigators of GSK sex-tape scandal to go public

China has abruptly changed course on its plans to prosecute private investigator Peter Humphrey and his wife Yu Yingzeng in a closed trial. Now Humphrey and Yu, who were arrested last summer as part of China's investigation of bribery charges involving GlaxoSmithKline, will be tried in a public proceeding.

New scrutiny for GlaxoSmithKline after news of 2001 bribery-related housecleaning in China

GlaxoSmithKline's bribery woes in China apparently go back a bit further than the $489 million scandal that broke last summer. The U.K. company has acknowledged that it fired about 30 staffers in its China vaccines business in 2001 after turning up evidence of corruption.

China indicts PI and his American wife for 'illegal' activities in GSK bribery probe

Two months after charging three China-based executives of GlaxoSmithKline with bribery, that country is coming down hard on a British private investigator and his wife for their alleged roles in the widening scandal. British private investigator Peter Humphrey and his wife Yu Yingzeng, who is an American, have been indicted for illegally collecting private information on Chinese citizens, according to the state's news agency, Xinhua.

China's HD Bio teams with Marshall U. for cancer R&D

Chinese clinical research outfit HD Biosciences has struck a deal with Marshall University to collaborate on cancer drug development, sharing costs and risks in hopes of commercializing new therapies.

Report: China animal vaccine market up by 26%

China's animal vaccine market grew a whopping 26% between 2004 and 2013, research from a new market report shows--and analysts say the market shows no sign of stopping anytime soon, forecasting further growth of 15% by 2016.

U.S. voices concern over closed trial of American linked to GSK scandal

Until now, the widening soap opera that has left GlaxoSmithKline facing bribery charges in China seemed to be Britain's problem. But now the United States is stepping in, as China moves to try an American in a secret courtroom procedure starting August 7.

China chooses closed trial for investigator linked to GSK bribery scandal

China's arrest of British private investigator Peter Humphrey and his American wife Yu Yingzeng last summer was a shock to the pharmaceutical community, as Humphrey's firm, ChinaWhys, had long provided assistance to drug companies trying to navigate that country's complicated business environment. Now it looks as if the two are going to be tried privately--in a closed-trial procedure that China normally reserves for cases involving national security or state secrets.